David S. Krause, M.D.
David Krause, M.D. is Chief Medical Officer at Genomind, a private, venture-backed biotechnology company in King of Prussia PA. A native of Philadelphia, he attended Temple University School of Medicine and trained in internal medicine at the Medical College of Pennsylvania and Temple University Hospital.
Following a decade in the practice of internal medicine, Dr. Krause spent 12 years at SmithKline Beecham and GlaxoSmithKline. The first 8 years of his career at SB were engaged in increasing areas of responsibility for SB&'s vaccine franchise in the U.S., where he led the successful North American development of hepatitis A vaccine, acellular pertussis vaccine, and several novel combination vaccines.From 1998-2000 he led several worldwide clinical development groups within SB, including the Inflammation, Tissue Repair, and Oncology (ITRO) and Pulmonary and Diabetes therapeutic areas. Upon the merger of SmithKline and Glaxo, Dr. Krause assumed new responsibilities, including North America Health Outcomes and Policy Development.
Dr. Krause joined Vicuron Pharmaceuticals (then known as Versicor) in 2002, and assumed responsibilities for the clinical development of antibiotics directed at serious bacterial and fungal infections. On his watch the phase 3 programs for both products were completed on time, and the New Drug Applications submitted to the U.S. FDA. In 2005 Dr. Krause became Chief Medical Officer and Executive Vice-President of Vicuron, which later was acquired by Pfizer Pharmaceuticals.
In 2009 Dr. Krause helped launch Tarsa Therapeutics, which has since filed a New Drug Application with the U.S. FDA for its oral calcitonin for postmenopausal osteoporosis.
Since 2017 he has been CMO at Genomind, a genetic testing company operating in the neuropsychiatric therapeutic area.
Dr. Krause is the author of more than 40 scientific publications and abstracts and is a Fellow of the American College of Physicians. He was named Centennial Fellow by the College of Liberal Arts of the Pennsylvania State University. He has served as a consultant to the Department of Defense on infectious disease and vaccine-related issues.
Page last updated: August 28, 2020
Make a Donation That Will Save Lives
Your tax-deductible donation funds lung disease and lung cancer medical research, new treatments, efforts to stop COVID-19, ending youth vaping, lung health education and more. Now more than ever, your support is needed.
Thank you! You've been successfully subscribed to our newsletter!